Bausch & Lomb (TSX:BLCO) Notes Receivable : C$0 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Notes Receivable?

Bausch & Lomb's Notes Receivable for the quarter that ended in Dec. 2024 was C$0 Mil.

Bausch & Lomb Notes Receivable Historical Data

The historical data trend for Bausch & Lomb's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Notes Receivable Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Notes Receivable

Get a 7-Day Free Trial

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Bausch & Lomb Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Bausch & Lomb Notes Receivable Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

BLCO:USA

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Executives